Skip Navigation

Faculty Directory

Amita Gupta, MD

  • Associate Professor

Departmental Affiliations

  • School of Medicine (Primary)
  • International Health (Joint)
    • Division: Global Disease Epidemiology and Control

Center & Institute Affiliations

Contact Information

600 N. Wolfe Street
Phipps 540-B
Baltimore, Maryland 21287

410-502-7696
443-287-6440

Johns Hopkins Center for Clinical Global Health Education
Baltimore-Washington-India Clinical Trials Unit
RePORT International and India consortiums

View Current Courses

Education

MHS, Johns Hopkins Bloomberg School of Public Health, 2006
MD, Harvard Medical School, 1997

Overview

Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistance. Since 2002, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations, including the C-TRIUMPH and RePORT consortium for tuberculosis (TB) research funded by the US National Institutes of Health (NIH) and the government of India. Dr. Gupta is also Co-principal Investigator of the NIH-funded Baltimore-Washington-India (BWI) HIV and Infectious Diseases Clinical Trials Unit (CTU), and she is an active clinical investigator in multi-country HIV/TB trials conducted by the AIDS Clinical Trials Group (ACTG) and co-leads the TB scientific working groups of the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT)and NIH-funded IeDEA International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Additionally, she and her team have been awarded research grants from the NIH, CDC, Indian government, and several philanthropic foundations to investigate TB in children and pregnant women, malnutrition, infection and inflammation, HIV treatment outcomes, and antibiotic resistance. Dr. Gupta is an author of more than 170 peer-reviewed research publications and 7 book chapters, primarily on prevention and treatment of HIV, TB, and other infectious diseases, predominantly in low- and middle-income settings. She has also mentored more than 30 junior scientists in India and the US to run research studies and submit their own grants and scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention and at the JHU School of Medicine.

Honors and Awards

1991: MIT Women Studies Writing Prize “Women and AIDS in the United States: Unheard Voices”

1991: MIT Student Humanitarian Award

1991: Sigma Xi Research Honor Society

1993: Harvard Medical School Urban Health Fellowship

1996: Paul Dudley White & Andrew Sellard Traveling Fellowship

2000: IDSA Special Citation for Fellows-in-Training

2001: Reza Gandeji Award (UCSF resident award for medical ethics and compassionate patient care)

2002: Mackel Finalist, Epidemic Intelligence Service Conference, Centers for Disease Control and Prevention

2002: U.S. Public Health Service Award for Bioterrorism Surveillance Post 9/11

2002: U.S. Public Health Service Award for Foreign Duty Service (cholera in Micronesia)

2017: Invited Member, Women in Global Health Advisory Board, Cornell University

2007: Clinician Scientist Award, Johns Hopkins University School of Medicine

2018: Honored as one of “Hopkins Heroes,” Johns Hopkins School of Medicine

2019: Invited to be a member of the NIAID National Advisory Allergy and Infectious Diseases Council

  • Infectious diseases in India
  • HIV and malnutrition
  • TB cohorts in India
  • acute febrile illness
  • TB in pregnancy
  • TB preventive therapy trials in adults, children, pregnant women
  • MDR TB Clinical trials of diagnostics
  • preventive therapies
  • and treatments
  • observational cohort studies
  • Tuberculosis and HIV
  • India
  • Low and middle-income countries
  • Interactions of infectious and chronic diseases
  • TB biomarker research
  • Antimicrobial resistance
  • Maternal and child health
  • Pregnancy
  • pediatrics
  • adults
  • household contacts.

Selected Publications

  • Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.
  • Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC (2019) Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med 16(8): e1002882. https://doi.org/10.1371/journal.pmed.1002882. PMID: 31415563; PMCID: PMC6695091.
  • Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, Dawson R, Mave V, Sanchez J, Mendoza A, Gonzales P, Kumarasamy N, Comins K, Conradie F, Shenje J, Fontain SN, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo UG, Ferreira ACG, Mugah C, Harrington M, Jones L, Cox S, Smith B, Shah NS, Hesseling AC, Churchyard G, ACTG 5300/IMPAACT I2003 PHOENIx Feasibility study team. Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2019 Mar 28. pii: ciz235. doi: 10.1093/cid/ciz235. [Epub ahead of print] PMID: 30942853
  • Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia JV, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011. DOI: 10.1056/NEJMoa1806808.
  • Thomas BE, Thiruvengadam K, S R, Kadam D, Ovung S, Sivakumar S, Bala Yogendra Shivakumar SV, Paradkar M, Gupte N, Suryavanshi N, Dolla CK, Gupte AN, Kohli R, Pradhan N, Sivaramakrishnan GN, Gaikwad S, Kagal A, Dhanasekaran K, Deluca A, Golub JE, Mave V, Chandrasekaran P, Gupta A; CTRIUMPh RePORT India Study. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored. PLoS One 2019 Jul 31;14(7):0220507. doi: 10.1371/jounal.pone.0220507. eCollection 2019. PMCID:PMC6668833